INTRODUCTION {#s1}
============

Follicular lymphoma (FL) is the most common indolent lymphoma in the United States and Western Europe ([@MCS004614BELC77]). The clinical course is generally mild, but transformation into a more aggressive lymphoma occurs at a rate of ∼3% per year ([@MCS004614BELC3]; [@MCS004614BELC54]). Most cases of FL transformation result in diffuse large B-cell lymphoma, but, rarely, lymphoblastic lesions comprised of immature rather than mature B cells can arise, typically in younger patients ([@MCS004614BELC17]; [@MCS004614BELC24]; [@MCS004614BELC39]; [@MCS004614BELC76]; [@MCS004614BELC92]). Although the mechanisms underlying transformation to diffuse large B-cell lymphoma have been extensively examined ([@MCS004614BELC69]; [@MCS004614BELC64]), molecular characterization of the "dedifferentiation" to B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) has been very limited thus far ([@MCS004614BELC26]; [@MCS004614BELC75]). Here we present a case of an FL transformed into B-cell B-ALL/LBL with extensive molecular characterization including analysis of the somatic hypermutation (SHM) status of the immunoglobulin (Ig) genes, cytogenetic studies, and whole-exome sequencing (WES) of the patient\'s normal, FL, and B-ALL/LBL tissues.

RESULTS {#s2}
=======

Clinical History {#s2a}
----------------

The patient was a 36-yr-old male diagnosed in June 2015 with low-grade FL based on an excisional biopsy of an enlarged right groin lymph node. A concurrent bone marrow (BM) biopsy also showed involvement of FL. The patient did not receive any chemotherapy by his own decision. In August 2016, he presented with fatigue, fevers, night sweats, and right lower extremity/groin swelling. A CT scan showed bulky, multifocal lymphadenopathy. Biopsy of the right groin lesion revealed B-lymphoblastic lymphoma. Intensive chemotherapy was initiated, but the disease progressed, including eventual appearance of circulating lymphoblasts (a leukemic phase), and the patient passed away in 2017.

Histology, Immunohistochemistry, and Flow Cytometry Analysis {#s2b}
------------------------------------------------------------

The original lymph node biopsy from 2015 shown in [Figure 1](#MCS004614BELF1){ref-type="fig"} displayed markedly expanded follicles, composed predominantly of small centrocytes with scattered larger centroblasts (\<5/hpf). There were neither clusters nor sheets of centroblasts outside of the follicles. Immunohistochemical stains showed that the neoplastic lymphocytes were positive for CD20, PAX5, CD10, BCL2, and BCL6, with a Ki-67 index of ∼10% and minimal MYC expression. CD21 highlighted intact follicular dendritic cell meshworks throughout the section. The staging bone marrow biopsy showed paratrabecular aggregates of small lymphocytes, accounting for 40% of marrow cellularity. Flow cytometry of the marrow aspirate revealed that these cells were clonal, lambda-restricted CD5^−^, CD10(var)^+^, CD19^+^, CD20^+^, and CD23^+^ B cells, supporting the diagnosis of marrow involvement by FL.

![Tumor histopathology and immunohistochemistry of follicular lymphoma (FL). (*A*) Excisional biopsy of a lymph node with FL in 2015 stained for hematoxylin and eosin (magnification at 4× \[*upper left*\] and 40× \[*upper right*\]). (*B*) BCL2 and TdT immunohistochemical stains are shown on the *lower left* and *lower right* (magnification at 4× and 40×, respectively).](MCS004614Bel_F1){#MCS004614BELF1}

The 2016 lymph node biopsy (see [Fig. 2](#MCS004614BELF2){ref-type="fig"}) showed a diffuse infiltrate consisting predominantly of large atypical lymphoid cells. Focally, macrophages with intracellular debris were noted, a finding indicative of high-grade malignancy with substantial cell death. The neoplastic cells were positive for PAX-5, CD79a, CD10, BCL2, MUM1, and, notably, TdT, with a Ki-67 index as high as ∼80%. In contrast to the 2015 biopsy, the neoplastic cells in 2016 were negative for CD20 and BCL6, but MYC staining was now positive in ∼70% of the neoplastic cells. Flow cytometry demonstrated that these malignant cells were positive for CD45(dim), CD19, CD79a, CD10, and TdT, consistent with B-cell lymphoblasts. A tandem BM biopsy did not reveal lymphoma. However, in 2017 BM and peripheral blood displayed extensive involvement by the B-ALL/LBL.

![Tumor histopathology and immunohistochemistry of B-lymphoblastic leukemia/lymphoma (B-ALL/LBL). (*A*) Excisional biopsy of a lymph node with B-ALL/LBL in 2016 stained for hematoxylin and eosin (magnification at 4× \[*upper left*\] and 40× \[*upper right*\]). (*B*) BCL2 and TdT immunohistochemical stains are shown on the *lower left* and *lower right* (magnification at 40× for each).](MCS004614Bel_F2){#MCS004614BELF2}

Analysis of SHM of Ig Genes {#s2c}
---------------------------

To further characterize the FL and B-ALL/LBL, we performed NGS sequencing of Ig rearrangements from normal (reactive lymph node), FL, and B-ALL/LBL specimens. In the FL, a single neoplastic clone (*IgHV4-34*\_*JH6*) predominated, accounting for ∼99% of the identified *IgH* rearranged clones ([Supplemental Figs. 1 and 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004614/-/DC1)). A considerable degree of SHM was evident in this clone, with a median of 130--139 mutated nucleotides per 1000 bp ([Fig. 3](#MCS004614BELF3){ref-type="fig"}). This high level of SHM can be found in FLs ([@MCS004614BELC22]; [@MCS004614BELC88]; [@MCS004614BELC12]).

![High levels of somatic hypermutation (SHM) in the heavy chain sequences of the dominant clone in the FL. (*A*) The percentage of unique heavy chain sequences of the clone is plotted versus the percentage of mutation in nucleotides from the germline. (*B*) IgBLAST alignment of highest copy *IgH* gene rearrangement in the dominant clone showing multiple mutations in both the nucleotide and amino acid sequence compared to the nearest germline *VH* gene, *VH4-34*.](MCS004614Bel_F3){#MCS004614BELF3}

When examining the heavy and light chain Ig gene rearrangements of the B-ALL/LBL, surprisingly no dominant clone was evident. Instead, a wide variety of different rearrangements were identified, spanning many *VH* and *JH* genes ([Supplemental Figs. 1 and 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004614/-/DC1); [Supplemental Tables 1 and 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004614/-/DC1)). The sequence easily attributable to the IgVH4-34 clone seen in the FL accounted for \<1% of the rearrangements sequenced in the leukemia sample. Lambda light chain rearrangement analysis showed somewhat more identifiable overlap between the FL and B-ALL/LBL samples. Similar results were obtained using polymerase chain reaction (PCR)-based molecular studies for *IgH* gene rearrangement performed on the biopsies in the clinical laboratory. FL was positive for clonality with prominent peaks (Framework 2: 265/266-bp peaks) but B-ALL/LBL was negative and showed only a low amplitude of *IgH* amplification consistent with the lack of an identifiable dominant clone.

Given that the B-ALL/LBL clearly emerged from the FL as evidenced by the fluorescence in situ hybridization (FISH) and WES data (please see the paragraphs below), this lack of an identifiable dominant clone at the B-ALL/LBL stage likely stems from the extreme SHM upon the disease progression. SHM in advanced FL or, in particular, transformed to diffuse large B-cell lymphoma can be very extensive ([@MCS004614BELC88]; [@MCS004614BELC12]), even involving non-Ig gene loci ([@MCS004614BELC62]; [@MCS004614BELC69]). Accordingly, lineage tracing of the dominant FL rearrangement in our case showed that some B-ALL/LBL clones were identified in distal portions and even in distinct branches of the FL lineage tree ([Fig. 4](#MCS004614BELF4){ref-type="fig"}). This pattern is consistent with the occurrence of "complex evolution" of the FL ([@MCS004614BELC50]) with the relatedness between the Ig clones in the FL and B-ALL/LBL being only partially traceable among the recovered (sequenced) Ig gene rearrangements.

![Lineage tree of the dominant FL clone. The dominant heavy chain gene rearrangement in the FL sample was tracked through lymph node samples from the FL and the B-ALL/LBL. A lineage tree structure was inferred as described in Methods. 5360 sequence copies are derived from the FL samples and 127 sequence copies are derived from the B-ALL/LBL sample. In the tree, black nodes are inferred, red nodes (located in the leaves of the tree) represent sequences in the FL, and green nodes represent sequences in the B-ALL/LBL (*inset*). There are no nodes that are shared between the leukemia and lymphoma samples. Branch length (scale) is proportional to the number of mutations between a node and its parent.](MCS004614Bel_F4){#MCS004614BELF4}

Karyotype and FISH Findings {#s2d}
---------------------------

Although conventional cytogenetics showed a normal male karyotype 46,XY\[20\], FISH studies with gene break-apart probes performed on the 2015 FL-containing BM specimen were positive for rearrangements of *BCL2* and *BCL6* genes; the latter rearrangement is often associated with increased clinical aggressiveness of the disease ([@MCS004614BELC2]). In contrast, no *MYC* gene rearrangement was identified at that time. Unexpectedly, FISH for *IgH*-*BCL2* gene fusion was also negative, but sampling limitations or excessive tissue fixation may have diminished the sensitivity of detecting an *IgH*-*BCL2* gene rearrangement in the lymph node.

FISH studies performed on the 2016 B-ALL/LBL-containing node biopsy were also positive for both *BCL2* and *BCL6* gene rearrangements as well as *MYC* gene rearrangement absent in FL. The rearrangement involving *MYC*, a potent oncogene, most likely played a key role in this transformation. *MYC* translocations are well-known to contribute to high aggressiveness of lymphomas and are a hallmark of FL-B-ALL/LBL transformation ([@MCS004614BELC86]; [@MCS004614BELC92]; [@MCS004614BELC26]; [@MCS004614BELC75]; [@MCS004614BELC47]). Interestingly, single-cell RNA-seq data in murine models have shown that *MYC* activity can predict reprogramming efficiency across many somatic cell types ([@MCS004614BELC23]), emphasizing a potential element of "dedifferentiation" in these transformations.

Cytogenetic analysis of the 2017 bone marrow involved by B-ALL/LBL revealed a highly abnormal karyotype: 47,XY,+X, add(3)(q27), del(3)(q27),der(8), t(1;8)(q21;p23),t(8;14)(q24;q32),14,ider(14)(q10)t(8;14),dup(17)(q21q25),+18,der(18),t(14;18)(q32;q21)\[20\]/46,XY\[4\]. The simultaneous FISH studies were positive for *BCL2*, *BCL6*, and *MYC* gene rearrangements, but did identify a t(14;18) *IgH*-*BCL2* translocation (because this was done in BM aspirate, the ability to detect *IgH*-*BCL2* may have been higher as compared to the prior lymph node specimens). Overall, at least three different translocations were identified in this transformed, clinically advanced B-ALL/LBL with the t(8:14) involving the *MYC* gene occurring at this latter stage of the patient\'s lymphoma.

Genomic Sequencing Analyses {#s2e}
---------------------------

Clinical next-generation sequencing analyses using a targeted hematologic malignancy panel of 54 genes were largely negative. No pathogenic variants were identified, and only a single variant of uncertain significance was identified in *SETBP1* (p.V428M c.1282G \> A) in the BM aspirate from 2017 involved by B-ALL/LBL. No variants were identified in the lymph node from 2016.

Next, an experimental comparative WES of the patient\'s normal tissue and the diagnostic biopsies from 2015 (FL) and 2016 (B-ALL/LBL) was performed in an attempt to better characterize the FL-B-ALL/LBL neoplastic progression scenario. We focused on mutations with high allelic frequencies (\>30%) to identify potential "drivers" of the disease and its progression. A total of 751 single-nucleotide variants (SNVs) were identified ([Fig. 5](#MCS004614BELF5){ref-type="fig"}). Normal tissue contained only a fraction (111) of such mutations including 13 shared with FL and 38 with both FL and B-ALL/LBL. In turn, FL contained a total of 116 mutations. In addition to the 51 shared with either normal or normal and B-ALL/LBL cells, FL also shared 11 mutations solely with B-ALL/LBL; this pattern further supports the FISH findings that the B-ALL/LBL indeed emerged from the underlying FL. Strikingly, the B-ALL/LBL acquired as many as 575 unique mutations at this posttransformation stage of the lymphoma.

![Number of variants by whole-exome sequencing (WES). The total number of single-nucleotide variants (SNVs) of each sample and the overlap of the SNVs between the samples is shown on the *left* and the *right*, respectively. Only variants that had an allele fraction ≥0.3 and a read depth ≥10 are included here.](MCS004614Bel_F5){#MCS004614BELF5}

Characteristics of the Key Mutated Genes {#s2f}
----------------------------------------

At least some of the mutations highlighted as potentially oncogenic ([Table 1](#MCS004614BELTB1){ref-type="table"}) may have contributed to disease development and transformation to B-ALL/LBL by dysregulating two main cellular functions: (1) epigenetic control of gene expression and its consequences, including pathways in histone methylation, transcription, chromatin structure, and cellular differentiation (KDM6A, KMT2D, SMARCA4, TAF3, and CBX1), and (2) DNA repair (JMY, TAF3, CBX1, KDM6A, and KMT2D). As noted, some of the mutations may affect both of these broadly defined key cell functions, and the associated cellular programs may sometimes, if not often, be intricately interwoven. Within this selected group of mutations, the *TAF3* variant was the only one shared by normal and malignant cells and may have contributed to a predisposition for the development of FL at an early age. In turn, the nonsense mutation in *KMT2D* was the only one identified in both FL and B-ALL/LBL, perhaps contributing to the development of FL. The remaining mutations were all identified at the B-ALL/LBL stage only, indicating they might have played a role in driving the transformation to the aggressive lymphoblastic phase.

###### 

Molecular characteristics of the identified key potentially oncogenic mutations

  Gene        Chromo some   HGVS DNA reference   HGVS protein reference   Variant type   dbSNP/ dbVar ID                         Genotype (heterozygous/homozygous)   Predicted effect                                           Allele fraction (LL only unless otherwise stated)   Target coverage (LL only unless otherwise stated)
  ----------- ------------- -------------------- ------------------------ -------------- --------------------------------------- ------------------------------------ ---------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  *CBX1*      17.46154253   c\. 114G \> C        p.Y38\*                  Nonsense                                               Heterozygous                         Epigenetic dysfunction, DNA repair                         0.44                                                18
  *KDM6A*     X.44820595    c\. 292C \> T        p.Q98\*                  Nonsense                                               Heterozygous                         Epigenetic dysfunction, DNA repair                         0.4                                                 30
  *SMARCA4*   19.11132626   c.2842G \> A         p.A948T                  Missense                                               Heterozygous                         Dominant negative, epigenetic dysfunction                  0.43                                                14
  *KMT2D*     12.49425446   c.13039\_ 13040del   p.Q4347Gfs\*24           Frameshift                                             Heterozygous                         Epigenetic dysfunction, DNA repair                         0.39 (LL)/0.22 (FL)                                 56 reads (LL)/173 reads (FL)
  *JMY*       5.78610468    c\. 2453C \> T       p.P818L                  Missense       rs778673068, COSM3618067, COSM3618068   Heterozygous                         DNA repair                                                 0.5                                                 12
  *TAF3*      10.8007560    c\. 2087T \> A       p.V696E                  Missense                                               Heterozygous                         Epigenetic dysfunction, transcription stress, DNA repair   0.72 (LL)/0.52(FL)/0.42 normal tissue               129 (LL)/148(FL)/86 normal tissue

### Dysregulation of Histone H3K27 Methylation and Cellular Differentiation (KDM6A) {#s2f1}

Histone methyltransferases and demethylases are crucial for proper temporal regulation of gene expression and differentiation ([@MCS004614BELC48]). KDM6A (also known as UTX) functions as a histone H3K27 demethylase, removing the repressive H3K27 methylation mark to foster transcriptional gene activation ([@MCS004614BELC84]). There is strong evidence that loss-of-function mutations in *KDM6A*, an established tumor-suppressor gene, play a role in cancer progression ([@MCS004614BELC89]). Sequencing efforts of both hematologic and nonhematologic malignancies in humans support this notion ([@MCS004614BELC84]; [@MCS004614BELC82]; [@MCS004614BELC87]; [@MCS004614BELC13]; [@MCS004614BELC27]). Moreover, functional studies in model systems support the importance of KDM6A in regulating cellular differentiation ([@MCS004614BELC43]; [@MCS004614BELC21]; [@MCS004614BELC59]) and pluripotent stem cell formation ([@MCS004614BELC71]). Therefore, it is intriguing to hypothesize that loss of function of KDM6A contributed to dysregulated differentiation as this neoplasm evolved from FL to B-ALL/LBL, with "dedifferentiation" of malignant cells being the hallmark of this type of transformation ([@MCS004614BELC92]).

### Dysregulation of Histone H3K4 Methylation (KMT2D) and KMT2D/KDM6A Interplay {#s2f2}

A frameshift-based nonsense mutation was detected in *KMT2D* (*MLL2*), a H3K4 mono-methyltransferase that aids in the activation of gene expression and differentiation ([@MCS004614BELC60]; [@MCS004614BELC66]). *KMT2D* is one of the most frequently mutated genes in cancer, and loss-of-function mutations in this tumor suppressor are considered likely oncogenic drivers of B-cell lymphomas, FL in particular ([@MCS004614BELC55]; [@MCS004614BELC63]; [@MCS004614BELC13]). It has been suggested that *KMT2D* (*MLL2*) variants are late events in the evolution of FL ([@MCS004614BELC28]) and, hence, may have predisposed to B-ALL/LBL transformation in our case.

Of interest, trimethylations of histone H3 at lysine 4 (H3K4) and lysine 27 (H3K27) are typically associated with gene activation and silencing, respectively ([@MCS004614BELC70]; [@MCS004614BELC67]; [@MCS004614BELC74]). This histone trimethylation balance can even be altered in coordinated fashion to modulate transcriptional programs integral to cellular function and development ([@MCS004614BELC6]; [@MCS004614BELC8]; [@MCS004614BELC33]). Given the nonsense mutations of both *KDM6A* and *KMT2D* genes in our patient\'s lymphoma, functionality of H3K27 and H3K4 was likely strongly dysregulated.

### Dysregulation of Chromatin Structure (SMARCA4, CBX1) {#s2f3}

Another mutation of interest in this case is *SMARCA4* A948T. SMARCA4 has a known role in cancer and has been typically considered a tumor suppressor gene, although there has been some recent debate of the exact role it plays in malignant cells ([@MCS004614BELC13]; [@MCS004614BELC29]). SMARCA4 functions in a SWI/SNF complex, regulating chromatin remodeling to control gene expression, perhaps requiring KDM6A ([@MCS004614BELC53]).

The mutation identified in this patient falls in a span of an amino acid domain within which hotspot point mutations have been shown to induce a dominant negative effect ([@MCS004614BELC30]). Although *SMARCA4* A948 is not one of the hotspot amino acids specifically examined in that study, residues nearby on both sides of A948 were shown to affect the DNA binding groove. Using published methods for modeling SMARCA4 structure using atomic coordinates ([@MCS004614BELC30]), we observe that the A948 residue also lies on an exposed surface residue in or near the DNA binding groove (data not shown). Because the A948T missense mutation replaces a hydrophobic residue with a polar residue, this change could also alter DNA binding. The A948T mutation is novel, and A948V mutation (a more conservative change than A948T) has been reported and is predicted to be pathogenic ([@MCS004614BELC72]; [@MCS004614BELC79]).

Notably, SMARCA4 also interacts with MYC ([@MCS004614BELC19]). Given the *IgH* gene translocation-driven increase in MYC expression demonstrated in this patient\'s lymphoblastic lymphoma, it is reasonable to speculate that oncogenicity of the constitutively overexpressed MYC is even further perturbed by the mutated SMARCA4.

Another mutant that may dysregulate chromatin structure and gene expression is *CBX1* p.Y38\*. *CBX1* (also referred to as *HP1-Beta*) encodes Chromobox protein homolog 1, a heterochromatic adaptor molecule implicated in both gene silencing and supranucleosomal chromatin structure ([@MCS004614BELC41]). Nonsense mutations of *CBX1* have not been identified in the general population ([@MCS004614BELC44]), and they have been only rarely seen in cancer thus far ([@MCS004614BELC79]).

### Dysregulation of DNA Repair (JMY, KDM6A, KMT2D, and CBX1) {#s2f4}

The high mutation rate and chromosomal instability seen in B-ALL/LBL in this case may be due to defects in the transcriptional regulation of DNA repair pathways. The *JMY* P818L mutation may weaken DNA repair mechanisms. JMY functions as a transcriptional coactivator in the p53 pathway to respond to DNA damage ([@MCS004614BELC1]). The P818L missense mutation occurs in a proline-rich stretch of the protein ([@MCS004614BELC81]) and is classified as likely pathogenic ([@MCS004614BELC72]). The P818L mutation has not been identified in healthy individuals ([@MCS004614BELC44]) yet and has so far been noted in two cancer cases, albeit nonlymphoid ([@MCS004614BELC79]).

In addition to their roles in cell differentiation, loss of function of KDM6A, KMT2D, and CBX1 have each been implicated in the DNA damage response and genome instability. *KMT2D* loss can lead to genomic instability via transcriptional stress ([@MCS004614BELC36]), heterozygous loss of *CBX1* may be sufficient to cause dysfunction in the DNA damage response and lead to genomic instability ([@MCS004614BELC4]; [@MCS004614BELC5]; [@MCS004614BELC91]), and inhibition of KDM6A may affect DNA damage, specifically during vulnerable states of differentiation ([@MCS004614BELC31]). These findings suggest that the mutations identified in this study may affect DNA repair.

### Potential Germline Predisposition to Dysregulation of DNA Repair and Epigenetic Control of Cellular Function (TAF3) {#s2f5}

Finally, the *TAF3* p.V696E mutant may alter the regulation of transcription, cell fate, pluripotency, and DNA repair ([@MCS004614BELC61]; [@MCS004614BELC35]; [@MCS004614BELC40]; [@MCS004614BELC48]). Although, the mutation reported here is novel, it occurs at an amino acid position with common SNPs in the general population (e.g., rs10795583). It is important to note, however, that the common SNPs are conservative changes (p.V696L or p.V696A) that are not likely to have a large impact on protein function. On the other hand, p.V696E represents a nonconservative amino acid change that is more likely to impact function of TAF3. TFIID, the highly conserved transcription factor for RNA polymerase II, binds directly to H3K4me3 via TAF3, stimulating preinitiation complex formation ([@MCS004614BELC85]; [@MCS004614BELC42]).

TAF3 functions at least in part through its interactions with H3K4 methylated histones, controlling the function of many transcription factors, including some that can induce pluripotency ([@MCS004614BELC61]; [@MCS004614BELC35]; [@MCS004614BELC40]; [@MCS004614BELC48]). Moreover, the interaction of TAF3 and histones methylated at H3K4 may inhibit p53-dependent regulation of genes upon genotoxic insult ([@MCS004614BELC7]; [@MCS004614BELC42]). Because we identified the *TAF3* V696E mutation in normal cells, and it was conserved in both FL and B-ALL/LBL, this potentially germline alteration might have predisposed to the lymphoma development by affecting the baseline of cellular differentiation programs or DNA repair.

DISCUSSION {#s3}
==========

We present here extensive molecular characterization of a rare clinical case of a 36-yr-old patient with a FL, which transformed into a B-lymphoblastic leukemia/lymphoma roughly 1 yr after the initial diagnosis without any intervening medical treatment. The B-ALL/LBL transformation was ultimately followed by the patient\'s demise within the following year. This aggressive clinical course appears to be typical in the patients with FL-B-ALL/LBL progression ([@MCS004614BELC26]; [@MCS004614BELC75]).

We identified a marked degree of SHM in the FL and it has been previously demonstrated that SHM increases during transformation from FL to DLBCL, starting from a known high baseline in FL ([@MCS004614BELC50]). The SHM may have even "spilled over" to other gene loci, as reported previously in transformations to DLBCL ([@MCS004614BELC62]; [@MCS004614BELC69]). Our findings suggest that FL to B-ALL/LBL transformation is associated with particularly robust SHM, rendering in our case most of the mutated immunoglobulin gene sequences virtually unrecognizable/unamplifiable by standard PCR primers and helping to explain why we could not identify the dominant malignant clone at the advanced, B-ALL/LBL stage of the disease. Nevertheless, we did find some similarities between the highly SHM-changed Ig clones recovered in the FL and B-ALL/LBL, supporting the conclusion of high Ig mutational rate present at the B-ALL/LBL stage.

The clinical, cytogenetic, and WES data, together with the existing literature, clearly point toward the clonal relationship between FL and B-ALL/LBL in this patient. Not only did the B-ALL/LBL follow the FL within 1 yr without any mutagenic therapy, but there were at least three pathogenic translocations, two of which (*BCL2* and *BCL6*) overlapped between the FL and B-ALL/LBL. The addition of the *MYC* rearrangement matches all other cases of B-ALL/LBL transformed from FL ([@MCS004614BELC26]; [@MCS004614BELC75]) and a clonal relationship between FL and B-ALL/LBL was established in all of these cases. Moreover, mechanistic roles for MYC in oncogenesis, genetic instability, aggressive transformations of lymphomas, and transdifferentiation have been previously demonstrated and further support this rearrangement as an important contributor to LL transformation ([@MCS004614BELC57]; [@MCS004614BELC64]; [@MCS004614BELC23]). WES analysis further indicates that B-ALL/LBL clonally emerged from the FL. FL and B-ALL/LBL shared 11 tumor-specific point mutations, and no point mutations were common to normal cells and B-ALL/LBL but absent in FL, again supporting the scenario of FL to B-ALL/LBL progression.

It is important to note that this transformed B-ALL/LBL seems to be quite distinct from the "standard" de novo B-ALL/LBL. B-ALL/LBL transformed from FL is universally clinically more aggressive, with a unique molecular and genetic profile, including MYC gene translocation and, as we show, a much higher tumor mutational burden (TMB) than typically seen in de novo B-ALL/LBL ([@MCS004614BELC49]; [@MCS004614BELC14]). Therefore, it has suggested that transformed malignant tumors such as these be alternatively referred to as high-grade B-cell lymphoma with blastic features and TdT-expression ([@MCS004614BELC56]). However, based on the progenitor B-cell phenotype and blastic morphology, we have chosen to call this case a transformation of FL to B-ALL/LBL, as typically done by others ([@MCS004614BELC26]; [@MCS004614BELC75]) to follow the current WHO 2017 classification ([@MCS004614BELC77]).

Of note, even relative to the other two FL-B-ALL/LBL cases in which WES was performed, the "explosion" of point mutations (575) identified by us solely at the B-ALL/LBL stage is remarkable ([@MCS004614BELC26]; [@MCS004614BELC75]). This high mutational index suggests the possibility of impaired DNA repair mechanisms. In addition, several variants that may have dysregulated transcriptional programs and cellular differentiation were identified, at least to some degree by epigenetic dysregulation; the process is considered to play a key role in lymphomagenesis ([@MCS004614BELC18]). Given the additional aspect of "dedifferentiation" implied by this lymphoblastic transformation, mutations that affect these epigenetic pathways may be of particular importance in this context. Intriguingly, one of the two other published cases of a similar transformation in which WES was performed showed likely loss of function of both KMT2D and SMARCA2, a related protein to SMARCA4, albeit with unique features ([@MCS004614BELC75]; [@MCS004614BELC29]). This may represent an overlapping mechanism in these transformations. However, given that *KMT2D* mutations are common in FL ([@MCS004614BELC55]), the mutations may be associated with biological progression of FL in general, rather than B-ALL/LBL transformation specifically.

Finally, the identified mutational profile may have potential implications for therapy of the FL-B-ALL/LBL transformation, which appears particularly difficult to treat. It is becoming increasingly evident that mutations in epigenetic modifier genes may be actionable. FLs often demonstrate pathogenic driver mutations in epigenetic modifier genes, such as *KMT2D* and *EZH2*, among others ([@MCS004614BELC10]; [@MCS004614BELC58]; [@MCS004614BELC38]; [@MCS004614BELC90]). Our case study appears to align with that trend, and the combination of mutations in epigenetic modifier genes suggests potential efficacy in therapeutics that target epigenetics, even at the B-ALL/LBL stage. Accordingly, loss-of-function mutations in *KDM6A* (H3K27me3 demethylase) seen in our case suggest inhibiting H3K27 methylation may prove therapeutically effective. Indeed, inhibitors of EZH2 (a H3K27me3 methyltransferase) show promise in clinical trials of advanced FL ([@MCS004614BELC65]; [@MCS004614BELC34]). Interestingly, it has recently been shown that KDM6A loss can affect therapeutic response to EZH2 inhibitors in multiple myeloma and bladder cancer ([@MCS004614BELC20]; [@MCS004614BELC45]). Furthermore, given the presence of a potentially dominant negative *SMARCA4* mutation, this therapeutic approach may have been particularly appropriate because EZH2 inhibitors may have more potent antitumor effects in some *SMARCA4*-deficient cancer models ([@MCS004614BELC15]).

In addition, HDAC inhibitors (HDACi) are another class of FDA-approved therapeutics targeting epigenetic modifiers. A mouse model of Kabuki syndrome, a congenital genetic disorder linked to loss of function of *KMT2D* or *KDM6A*, exhibited sensitivity to HDACi ([@MCS004614BELC9]). Because the B-ALL/LBL in this case demonstrated loss-of-function mutations in both of these genes associated with Kabuki syndrome, HDACi therapy may, perhaps, be considered in the future for B-ALL/LBL cases with similar mutations.

The potential therapeutic value of H3K4me3 lysine demethylase inhibitors is also worth mentioning in the context of our mutational profile findings. Currently in development, these inhibitors have been reported to increase H3K4me3 levels with loss of function of KMT2D (H3K4me3 methyltransferase) and decrease cell proliferation in some cancer models ([@MCS004614BELC38]).

In summary, the combined findings reported here suggest a disease scenario in which transcriptional programs, cellular differentiation, and DNA repair mechanisms have been altered, perhaps in an interrelated fashion, leading to clonal "dedifferentiation" of a FL into a genetically unstable B-ALL/LBL. Therefore, the study provides new insights into the pathogenesis of FL-B-ALL/LBL transformation and suggests novel, disease biology--based therapeutic approaches to this aggressive and currently incurable disease.

METHODS {#s4}
=======

Clinical Data {#s4a}
-------------

All of the data was generated as a part of the routine clinical workup, including histology, immunohistochemistry, cytogenetics, FISH, and initial molecular genetic studies, which was performed in the anatomical and pathology laboratories at the Hospital of the University of Pennsylvania.

Sample Preparation for Whole-Exome and Immunoglobulin Rearrangement Gene Sequencing Studies {#s4b}
-------------------------------------------------------------------------------------------

DNA was isolated from formalin-fixed paraffin-embedded lymph node tissue sections using the DNeasy Tissue kit (QIAGEN) and underwent WES analysis at the Children\'s Hospital of Philadelphia core facility served by Beijing Genomic Institute (BGI). A reactive lymph node without lymphoma obtained from the patient was used to represent normal tissue.

Exome Sequencing, Alignment, and Variant Calling {#s4c}
------------------------------------------------

A whole-exome library was prepared using Agilent SureSelect Whole Exome v.5 kit sequencing, which was performed on the Illumina HiSeq 4000. After removal of low-quality base and trimmed adapter sequences by Cutadapt, the unaligned reads in FASTQ format were first filtered by Bowtie 2 for contaminants and evaluated by pre-alignment QA/QC, then aligned to the hg19 reference genome using Bowtie 2, TopHat 2.0, and STAR. Using Partek Flow pipeline variants, aligned reads were called by SAMtools mpileup 1.4.1 on all samples, annotated with SnpEff, VEP, and Ensembl Transcripts 75, and confirmed using IGV and GoldenHelix sequence browsers. Variants were filtered by reads number (cut off at 10) and high allele fraction (cut off at 30% for fixed essentially pure malignant cell populations). Mean coverage is 100×. Benign SNPs and indels were excluded using ExAC/gnomAD databases if they were present at \>0.1% population frequency in either database ([@MCS004614BELC44]).

Evaluation of Variant Oncogenicity {#s4d}
----------------------------------

A combination of approaches was integrated to project the pathogenic potential of the variants. First, the biological function of the specific variant in cancer was assessed using the OncoKB database ([@MCS004614BELC13]). Then, the functionality of the variant protein was estimated based on the nature of the mutation (e.g., early stop codon = likely loss of function unless published data suggested otherwise) and the importance of the variant protein in cancer-related pathways, including review of protein domain mapping in UniProt and/or PubMed. The abundance of the variant/nearby variants in cancer specimens in the COSMIC database ([@MCS004614BELC79]) versus general population in ExAC/gnomAD ([@MCS004614BELC44]) was also considered. Finally, some consideration was given to predictive algorithms (e.g., FATHMM, LoF score in ExAC) to help gauge the importance of protein and/or variant ([@MCS004614BELC72]; [@MCS004614BELC44]).

Sequencing Analysis of Immunoglobulin Gene Rearrangements {#s4e}
---------------------------------------------------------

*IgH*: Immunoglobulin heavy-chain family-specific (framework region (FR)1 primers) PCRs were performed on genomic DNA samples as described previously ([@MCS004614BELC52]), and sequencing was performed in the Human Immunology Core Facility at the University of Pennsylvania. Illumina 2 × 300-bp paired-end kits were used for all experiments (Illumina MiSeq Reagent Kit v3, 600-cycle, Illumina MS-102-3003).

*IgKappa and IgLambda*: Sequencing was performed with adapted Biomed-2 primer series ([@MCS004614BELC83]) and incorporated Illumina NexteraXT adapter sequences.

Kappa Light Chain Primers {#s4f}
-------------------------

NexteraXTR2-Hu-biomed2-Vk1f/6: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCAAGGTTCAGCGGCA GTGGATCTG-3′NexteraXTR2-Hu-biomed2-Vκ2f:5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGCCTCCATCTCCTGCAGGTCTAGTC-3′NexteraXTR2-Hu-biomed2-Vκ3f:5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCCAGGCTCCTCATCTA TGATGCATCC-3′NexteraXTR2-Hu-biomed2-Vκ4:5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAACTGCAAGTCCAGCC AGAGTGTTTT-3′NexteraXTR2-Hu-biomed2-Vκ5:5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCTGCAAAGCCAGCCA AGACATTGAT-3′NexteraXTR2-Hu-biomed2-Vκ7:5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACCGATTTCACCCTCA CAATTAATCC-3′NexteraXTR1-Hu-biomed2-Jκ1-4:5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTTACGTTTGATCTCCACCTTGGTCCC-3′NexteraXTR1-Hu-biomed2-Jκ5:5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGANCTTACGTTTAATCTCCAGTCGTGTCCC-3′

Lambda Light Chain Primers {#s4g}
--------------------------

NexteraXTR2-Hu-biomed2-Vλ1/2: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTCTCTGGCTCCAAGTCTGGC-3′NexteraXTR2-Hu-biomed2-Vλ3:5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGATCCCTGAGCGATTCTCTGG-3′NexteraXTR1-Hu-biomed2-Jλ1/2/3:5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTAGGACGGTGAGCTTGGTCCC-3′PCRs were performed on genomic DNA samples, and libraries were created under the same amplification and library preparation conditions as the *IgH* libraries.

Data Analysis {#s4h}
-------------

Repertoire sequencing data were analyzed using MiXCR (version 2.1.12), VDJtools (v1.1.10), and ImmuneDB as described in [@MCS004614BELC11]; [@MCS004614BELC73]; [@MCS004614BELC52]; and [@MCS004614BELC68]. Sequences with at least two copies were included in all analyses. For the heavy chain lineage analysis, sequencing data were analyzed with ImmuneDB v0.28.0 using the default settings for *IgH* sequencing ([@MCS004614BELC68]). Sequences with the same V-gene, J-gene, and CDR3 length having 85% amino acid similarity in the CDR3 were clustered together as clones. For the dominant clone in the lymphoma sample (*IgHV4-34*, *IgHJ6*, CARGVAVALHSSQNYMDVW) ImmuneDB was used to infer a lineage from the sequences with at least two copies and ETE3 ([@MCS004614BELC32]) was used to visualize the lineage tree structure in [Figure 4](#MCS004614BELF4){ref-type="fig"}.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Consent to deposit genomic data in publicly accessible databases could not be obtained prior to the patient passing away. The WESs from normal cells, FL, and lymphoblastic lymphoma have been deposited in the NCBI BioSample database (<https://www.ncbi.nlm.nih.gov/biosample/>) under accession numbers SAMN13114138, SAMN13114139, and SAMN13114140.
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